Tumor-Infiltrating Clonal Hematopoiesis

Oriol Pich(The Francis Crick Institute), Elsa Bernard(Institut Gustave Roussy), Maria Zagorulya(The Francis Crick Institute), Andrew Rowan(The Francis Crick Institute), Constandina Pospori(The Francis Crick Institute), Ramy Slama(University of Oxford), Hector Huerga Encabo(The Francis Crick Institute), Jennifer O’Sullivan(University of Oxford), Despoina Papazoglou(The Francis Crick Institute), Panayiotis Anastasiou(The Francis Crick Institute), Chrysante S. Iliakis(The Francis Crick Institute), Sally‐Ann Clark(University of Oxford), Krijn K. Dijkstra(The Francis Crick Institute), Vittorio Barbè(The Francis Crick Institute), C. Donovan Bailey(University College London Hospitals NHS Foundation Trust), Aaron J. Stonestrom(University of Maryland, Baltimore), Katey S.S. Enfield(The Francis Crick Institute), Mary Green(The Francis Crick Institute), Charlotte Brierley(University of Oxford), Alastair Magness(The Francis Crick Institute), David R. Pearce(The Francis Crick Institute), Robert E. Hynds(The Francis Crick Institute), Rija Zaidi(Cancer Research UK), Jayant K. Rane(The Francis Crick Institute), Ángel F. Álvarez-Prado(University Hospital of Lausanne), Kerstin Thol(Cancer Research UK), Rachel Scott(Cancer Research UK), Supreet Kaur Bola(Cancer Institute (WIA)), Elena Hoxha(Cancer Institute (WIA)), Steve Harris(UCL Biomedical Research Centre), Karl S. Peggs(University College London Hospitals NHS Foundation Trust), Sergio A. Quezada(Cancer Institute (WIA)), Allan Hackshaw(Cancer Research UK), Simone Zaccaria(Cancer Research UK), Johanna A. Joyce(University Hospital of Lausanne), Ilaria Malanchi(The Francis Crick Institute), Michael F. Berger(Memorial Sloan Kettering Cancer Center), Mariam Jamal-Hanjani(Royal London Hospital), Andreas Wack(The Francis Crick Institute), Julian Downward(The Francis Crick Institute), William Grey(University of York), Cristina Lo Celso(The Francis Crick Institute), Eva Grönroos(The Francis Crick Institute), Charles M. Rudin(Memorial Sloan Kettering Cancer Center), Adam J. Mead(University of Oxford), Dominique Bonnet(The Francis Crick Institute), Elli Papaemmanuil(Memorial Sloan Kettering Cancer Center), Charles Swanton(The Francis Crick Institute)
New England Journal of Medicine
April 23, 2025
Cited by 72Open Access
Full Text

Abstract

BACKGROUND: Clonal hematopoiesis of indeterminate potential (CHIP) is an age-related condition associated with increased mortality among patients with cancer. CHIP mutations with high variant-allele frequencies can be detected in tumors, a phenomenon we term tumor-infiltrating clonal hematopoiesis (TI-CH). The frequency of TI-CH and its effect on tumor evolution are unclear. METHODS: -mutant CHIP on the biologic features of lung tumors. RESULTS: mutations were the strongest genetic predictor of TI-CH; such mutations enhanced monocyte migration to lung tumor cells, fueled a myeloid-rich tumor microenvironment in mice, and resulted in the promotion of tumor organoid growth. CONCLUSIONS: TI-CH increased the risk of disease recurrence or death among patients with NSCLC and the risk of death from any cause among patients with solid tumors. TI-CH remodeled the tumor immune microenvironment and accelerated tumor organoid growth, findings that support a role for an aging-related hematologic clonal proliferation in cancer evolution. (Funded by the Royal Society and others.).


Related Papers

No related papers found

Powered by citation graph analysis